dabl Ltd is pleased to announce the appointment of Prof Desmond Fitzgerald MD, to the dabl Board of Directors.

Prof Fitzgerald has over 20 years experience in clinical pharmacology, currently serves as Vice-President for Research at University College Dublin and holds an Adjunct Chair in Medicine and Pharmacology at the University of Pennsylvania.

Prof Fitzgerald obtained his medical degree from UCD and subsequently trained in cardiology and clinical pharmacology at Vanderbilt University in the US. Following his return to Ireland, he was appointed to the post of Consultant Lecturer in Medicine and Therapeutics at the Mater Misericordiae University Hospital. In 1994, he was appointed Professor of Clinical Pharmacology at the Royal College of Surgeons in Ireland and Consultant in Clinical Pharmacology at Beaumont Hospital.

He established the Institute of Biopharmaceutical Sciences and Surgen, a pharmacogenetics company jointly owned by RCSI and the French genomics company, Genset. In 1999, he founded Java Clinical Research, a full service Clinical Research Organisation that specialises in cardiovascular clinical trials. Between 2004 and 2007, he was Chairman of the Health Research Board of Ireland.

Bill Rickard, Chairman of the Board of dabl Limited said, "We are delighted to welcome Des to the Board of Directors of dabl.  Having invested in a platform to take blood pressure monitoring during pharmacological trials to new levels, dabl has now embarked on an aggressive growth strategy which is driven by the increasing attention regulatory authorities are paying to the cardiovascular risk of new investigational drugs. Des’s experience and expertise fits very well with the input needed at this growth stage”.